Please use this identifier to cite or link to this item:
|Title:||Gemcitabine after bone marrow transplantation for refractory juvenile granulosa cell tumor|
|Authors:||Andrzej P. Kudelka|
Creigton L. Edwards
Claire F. Verschraegen
John J. Kavanagh
University of Texas MD Anderson Cancer Center
|Keywords:||Biochemistry, Genetics and Molecular Biology;Medicine;Pharmacology, Toxicology and Pharmaceutics|
|Citation:||Anti-Cancer Drugs. Vol.9, No.7 (1998), 621-623|
|Abstract:||A 19-year-old woman with refractory juvenile granulosa cell tumors had persistent disease after PVB (cisplatin, vinblastino and bleomycin) and multiple high doses of ICE (ifosfamide, carboplatin and etoposide) with peripheral stem cell support. She achieved stable disease for 4 months with low dose intensity gemcitabine of 500 mg/m2/week. The planned dose had been 1250 mg/m2/week. The dose intensity was limited by myelosuppression especially thrombocytopenia. The use of thrombopoietic, in addition to erythropoietic and myelopoletic, agents may permit higher dose intensity of gemcitabine after bone marrow ablative therapy with resulting greater anti tumor activity.|
|Appears in Collections:||Scopus 1991-2000|
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.